Molecular genetic and epigenetic mechanisms of primary and secondary resistance to imatinib mesylate treatment in ph chromosome positive chronic myeloid leukemia patients

Imatinib mesylate (IM) is a BCR-ABL targeted tyrosine kinase inhibitor drug used for frontline therapy in patients with chronic myeloid leukemia (CML). IM is highly effective and is considered the standard of care in CML management. Even though IM has become the gold standard frontline treatment...

全面介紹

Saved in:
書目詳細資料
主要作者: Elias, Marjanu Hikmah
格式: Thesis
語言:English
出版: 2015
主題:
在線閱讀:http://eprints.usm.my/40418/1/Dr._Marjanu_Hikmah_Elias_PhD-24_pages.pdf
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!